Johns Hopkins Gets $24M to Find Hepatitis B Cure

Three hundred million people worldwide live with hepatitis B, a lifelong viral infection that can lead to liver cancer and cirrhosis. Now, a global team of scientists just got the funding they need to change that.

Johns Hopkins Medicine will lead a multinational consortium that received a five-year, $24 million grant from the National Institutes of Health to find a cure for hepatitis B. The effort spans research groups in Brazil, India, Senegal, Uganda, and the United States.

"Although hepatitis B can be prevented by a safe and effective vaccine given shortly after birth, it's still a major health problem worldwide," says Dr. Chloe Thio, the consortium leader and infectious disease expert at Johns Hopkins. Access to the birth-dose vaccine remains limited in regions like the Western Pacific and Africa, where the virus hits hardest.

More than a million new cases appear each year, proving that prevention alone isn't enough. For the hundreds of millions already infected, a cure represents the only path forward.

The consortium's first year focuses on enrolling 675 participants with chronic hepatitis B, including some who also have HIV. These volunteers will form the foundation for all the consortium's research studies and provide crucial specimens like blood and liver tissue.

Seven specialized teams will tackle different pieces of the cure puzzle. Some will study how the virus reproduces and infects cells. Others will examine immune responses in blood and liver tissue during treatment. One team will use advanced gene sequencing to understand exactly how hepatitis B operates in the human body.

The researchers plan to identify biomarkers that show good control of the virus during treatment. They'll track hepatitis B surface antigen, a protein that helps diagnose active infections and monitor therapy responses.

The Ripple Effect

This research does more than hunt for a cure. The consortium is training the next generation of hepatitis B researchers at each collaborating center, building a pipeline of scientists dedicated to solving this global health challenge.

The team's approach could inform treatments for people living with both hepatitis B and HIV, addressing the complex ways these viruses interact. Understanding how to control one virus might unlock insights for treating both.

By studying specimens from diverse populations across multiple continents, researchers will gain a fuller picture of how hepatitis B behaves in different genetic and environmental contexts. This global perspective could lead to treatments that work for everyone, not just specific populations.

The consortium represents exactly what modern medical research should look like: collaborative, international, and focused on diseases that affect millions of people who've been waiting too long for answers. For three hundred million people living with hepatitis B, this $24 million investment isn't just funding research; it's funding hope that their lifelong infection might not have to be lifelong after all.